AbCellera Biologics (ABCL) Short term Debt: 2020-2025

Historic Short term Debt for AbCellera Biologics (ABCL) over the last 4 years, with Mar 2025 value amounting to $8.8 million.

  • AbCellera Biologics' Short term Debt fell 82.95% to $8.8 million in Q1 2025 from the same period last year, while for Mar 2025 it was $8.8 million, marking a year-over-year decrease of 82.95%. This contributed to the annual value of $8.1 million for FY2024, which is 83.98% down from last year.
  • Per AbCellera Biologics' latest filing, its Short term Debt stood at $8.8 million for Q1 2025, which was up 8.46% from $8.1 million recorded in Q4 2024.
  • AbCellera Biologics' Short term Debt's 5-year high stood at $54.9 million during Q2 2023, with a 5-year trough of $8.1 million in Q4 2024.
  • Over the past 3 years, AbCellera Biologics' median Short term Debt value was $42.9 million (recorded in 2023), while the average stood at $34.5 million.
  • As far as peak fluctuations go, AbCellera Biologics' Short term Debt soared by 195.99% in 2022, and later crashed by 83.98% in 2024.
  • Quarterly analysis of 5 years shows AbCellera Biologics' Short term Debt stood at $22.9 million in 2021, then skyrocketed by 92.77% to $44.2 million in 2022, then climbed by 14.17% to $50.5 million in 2023, then crashed by 83.98% to $8.1 million in 2024, then crashed by 82.95% to $8.8 million in 2025.
  • Its Short term Debt was $8.8 million in Q1 2025, compared to $8.1 million in Q4 2024 and $20.2 million in Q3 2024.